Related Experiment Video
Updated: Aug 5, 2026

09:06
Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
Published on: June 9, 2018
Revisiting the Link Between Huntington's Disease and Cancer: Evidence from the Enroll-HD dataset
Neuroepidemiology
|July 30, 2026
Summary
Huntington's disease (HD) does not show an overall protective effect against cancer. Cancer risk in HD patients is linked to disease stage and CAG repeat length, not a general protective mechanism.
Area of Science:
- Neurodegenerative Disorders
- Oncology
- Genetics
Background:
- Huntington's disease (HD) is a neurodegenerative disorder caused by CAG repeat expansion in the HTT gene.
- Previous research suggested a potential inverse relationship between HD and cancer, possibly due to pro-apoptotic mechanisms.
- This study investigates cancer prevalence in a large HD cohort and associated risk factors.
Purpose of the Study:
- To determine the prevalence of malignancies in a large cohort of individuals with Huntington's disease (HD).
- To explore demographic, genetic, and clinical factors influencing cancer risk in HD gene expansion carriers (HDGECs) and controls.
- To examine the association between cancer history and clinical outcomes in HD patients and controls.
Main Methods:
- Analysis of baseline data from the Enroll-HD PDS6 dataset (N = 24,686; 18,892 HDGECs, 5,794 controls).
- Cancer diagnoses identified using ICD-10 codes (C00-C97).
- Statistical comparisons using Chi-square, Mantel-Haenszel, and logistic regression models, controlling for age, sex, lifestyle, and CAG repeat length.
Main Results:
- Overall cancer prevalence was similar between HDGECs (4.92%) and controls (5.23%).
- Pre-motor-manifest HDGECs showed lower cancer prevalence (3.62%) compared to controls and motor-manifest patients (5.57%).
- Older age and female sex were risk factors for malignancy in both groups. Shorter CAG repeat length increased cancer prevalence only in HDGECs.
- Cancer history was associated with better baseline motor and functional outcomes in HDGECs, but worse outcomes in controls.
Conclusions:
- The study does not support a strong overall protective effect of HD against malignancy.
- Cancer prevalence in HD is associated with disease stage, age, and CAG repeat length.
- Lower cancer prevalence in premanifest HDGECs may involve biological factors and age-related confounding; further research is warranted.
Related Concept Videos
Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...
Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
Mouse Models of Cancer Study
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
